{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:54:54Z","timestamp":1781610894136,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The Deauville score is a key prognostic factor in Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL) during interim and end-of-treatment PET\/CT evaluations. However, additional measurements, particularly at baseline, such as metabolic tumour volume (MTV), total lesion glycolysis (TLG), and the maximum distance between hypermetabolic lymphoma lesions (Dmax) may offer enhanced prognostic value. This study evaluates the inter-reader agreement of these metrics to assess their reliability across different physicians.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This study included 117 patients with untreated HL or DLBCL who had baseline [\n                      <jats:sup>18<\/jats:sup>\n                      F]fluorodeoxyglucose PET\/CT scans. Nine nuclear medicine physicians independently segmented lymphoma lesions using the online platform Recomia (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.recomia.org\" ext-link-type=\"uri\">www.recomia.org<\/jats:ext-link>\n                      ), without specific instructions beyond identifying lymphoma-related lesions. MTV, TLG, and Dmax were calculated from these segmentations. MTV was defined as the summed volume in cm\n                      <jats:sup>3<\/jats:sup>\n                      , TLG as MTV multiplied by SUVmean and Dmax as the distance between the centroids of the two farthest lesions, measured in the 3D reconstruction. Each patient was segmented by two physicians. Inter-reader agreement was assessed using Spearman correlation coefficients for continuous values and Cohen\u2019s kappa coefficient (\u03ba) for dichotomized values (above\/below median).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mean age of the 117 patients was 50 years (standard deviation 19), 39% female. Median (\u00b1\u2009interquartile range) values were 321 (\u00b1\u2009597) cm\n                      <jats:sup>3<\/jats:sup>\n                      for MTV, 2200 (\u00b1\u20094399) cm\n                      <jats:sup>3<\/jats:sup>\n                      for TLG, and 35 (\u00b1\u200950) cm for Dmax. Spearman correlations between readers were 0.97 for MTV, 0.98 for TLG and 0.72 for Dmax (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). Agreement on dichotomized values was 95.7% for MTV (\u03ba\u2009=\u20090.91), 97.4% for TLG (\u03ba\u2009=\u20090.95), 83.8% for Dmax (\u03ba\u2009=\u20090.68).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MTV and TLG demonstrated good inter-reader reliability, even without standardized segmentation protocols. In contrast, Dmax showed moderate variability. These findings support the robustness of MTV and TLG as quantitative biomarkers. For Dmax to be clinically reliable, clearer segmentation guidelines are essential. Especially, inconsistent inclusion of small lesions that may not contribute significantly to MTV, might affect measurement of disease dissemination.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12880-025-01937-1","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T07:42:38Z","timestamp":1758094958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Inter-reader agreement of quantitative FDG PET\/CT biomarkers in lymphoma: a multicentre evaluation of MTV, TLG and Dmax"],"prefix":"10.1186","volume":"25","author":[{"given":"Elin","family":"Tr\u00e4g\u00e5rdh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Lewold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus Lopez","family":"Urdaneta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e5ns","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Enqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally F.","family":"Barrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Jerkeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Edenbrandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"Sadik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"1937_CR1","doi-asserted-by":"crossref","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, Schwartz LH, Zucca E, Fisher RI, Trotman J et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014, 32(27):3048\u20133058.","DOI":"10.1200\/JCO.2013.53.5229"},{"issue":"8","key":"1937_CR2","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1080\/10428190903040048","volume":"50","author":"M Meignan","year":"2009","unstructured":"Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the first international workshop on Interim-PET-Scan in lymphoma. Leuk Lymphoma. 2009;50(8):1257\u201360.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"1937_CR3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1182\/blood-2005-06-2252","volume":"107","author":"M Hutchings","year":"2006","unstructured":"Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, Buus S, Keiding S, D\u2019Amore F, Boesen AM, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in hodgkin lymphoma. Blood. 2006;107(1):52\u20139.","journal-title":"Blood"},{"issue":"8","key":"1937_CR4","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1200\/JCO.2009.25.4367","volume":"28","author":"JJ Cerci","year":"2010","unstructured":"Cerci JJ, Trindade E, Pracchia LF, Pitella FA, Linardi CC, Soares J Jr., Delbeke D, Topfer LA, Buccheri V, Meneghetti JC. Cost effectiveness of positron emission tomography in patients with hodgkin\u2019s lymphoma in unconfirmed complete remission or partial remission after first-line therapy. J Clin Oncol. 2010;28(8):1415\u201321.","journal-title":"J Clin Oncol"},{"issue":"9828","key":"1937_CR5","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","volume":"379","author":"A Engert","year":"2012","unstructured":"Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, Zijlstra J, Kral Z, Fuchs M, Hallek M, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage hodgkin\u2019s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379(9828):1791\u20139.","journal-title":"Lancet"},{"issue":"35","key":"1937_CR6","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1200\/JCO.2012.43.0934","volume":"30","author":"J Dupuis","year":"2012","unstructured":"Dupuis J, Berriolo-Riedinger A, Julian A, Brice P, Tychyj-Pinel C, Tilly H, Mounier N, Gallamini A, Feugier P, Soubeyran P, et al. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the groupe d\u2019etudes des lymphomes de l\u2019adulte and GOELAMS. J Clin Oncol. 2012;30(35):4317\u201322.","journal-title":"J Clin Oncol"},{"issue":"23","key":"1937_CR7","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2011.35.0736","volume":"29","author":"J Trotman","year":"2011","unstructured":"Trotman J, Fournier M, Lamy T, Seymour JF, Sonet A, Janikova A, Shpilberg O, Gyan E, Tilly H, Estell J, et al. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol. 2011;29(23):3194\u2013200.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1937_CR8","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00277-007-0356-9","volume":"86","author":"L Rigacci","year":"2007","unstructured":"Rigacci L, Vitolo U, Nassi L, Merli F, Gallamini A, Pregno P, Alvarez I, Salvi F, Sancetta R, Castagnoli A, et al. Positron emission tomography in the staging of patients with hodgkin\u2019s lymphoma. A prospective multicentric study by the intergruppo Italiano linfomi. Ann Hematol. 2007;86(12):897\u2013903.","journal-title":"Ann Hematol"},{"issue":"12","key":"1937_CR9","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1007\/s00259-010-1539-5","volume":"37","author":"L Le Dortz","year":"2010","unstructured":"Le Dortz L, De Guibert S, Bayat S, Devillers A, Houot R, Rolland Y, Cuggia M, Le Jeune F, Bahri H, Barge ML, et al. Diagnostic and prognostic impact of 18F-FDG PET\/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging. 2010;37(12):2307\u201314.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1937_CR10","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1186\/s12885-022-09758-z","volume":"22","author":"L van Heek","year":"2022","unstructured":"van Heek L, Stuka C, Kaul H, Muller H, Mettler J, Hitz F, Baues C, Fuchs M, Borchmann P, Engert A, et al. Predictive value of baseline metabolic tumor volume in early-stage favorable hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial. BMC Cancer. 2022;22(1):672.","journal-title":"BMC Cancer"},{"issue":"6","key":"1937_CR11","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1111\/ejh.14093","volume":"111","author":"L van Heek","year":"2023","unstructured":"van Heek L, Weindler J, Gorniak C, Kaul H, Muller H, Mettler J, Baues C, Fuchs M, Borchmann P, Ferdinandus J, et al. Prognostic value of baseline metabolic tumor volume (MTV) for forecasting chemotherapy outcome in early-stage unfavorable hodgkin lymphoma: data from the phase III HD17 trial. Eur J Haematol. 2023;111(6):881\u20137.","journal-title":"Eur J Haematol"},{"issue":"5","key":"1937_CR12","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/hon.2805","volume":"38","author":"E Zucca","year":"2020","unstructured":"Zucca E, Cascione L, Ruberto T, Facchinelli D, Schar S, Hayoz S, Dirnhofer S, Giovanella L, Bargetzi M, Mamot C, et al. Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38\/07 clinical trial. Hematol Oncol. 2020;38(5):715\u201325.","journal-title":"Hematol Oncol"},{"issue":"9","key":"1937_CR13","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1097\/MNM.0b013e32835673ec","volume":"33","author":"K Manohar","year":"2012","unstructured":"Manohar K, Mittal BR, Bhattacharya A, Malhotra P, Varma S. Prognostic value of quantitative parameters derived on initial staging 18F-fluorodeoxyglucose positron emission tomography\/computed tomography in patients with high-grade non-Hodgkin\u2019s lymphoma. Nucl Med Commun. 2012;33(9):974\u201381.","journal-title":"Nucl Med Commun"},{"issue":"6","key":"1937_CR14","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/cncr.27855","volume":"119","author":"TM Kim","year":"2013","unstructured":"Kim TM, Paeng JC, Chun IK, Keam B, Jeon YK, Lee SH, Kim DW, Lee DS, Kim CW, Chung JK, et al. Total lesion Glycolysis in positron emission tomography is a better predictor of outcome than the international prognostic index for patients with diffuse large B cell lymphoma. Cancer. 2013;119(6):1195\u2013202.","journal-title":"Cancer"},{"issue":"1","key":"1937_CR15","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s12672-025-02126-w","volume":"16","author":"Y Cui","year":"2025","unstructured":"Cui Y, Li Y, Hu W, Wu Z, Li S, Wang H. Evaluating deltamtv%, DeltaD(max)%, and %DeltaSUV(max) of (18)F-FDG PET\/CT for mid-treatment efficacy and prognosis in diffuse large B-cell lymphoma. Discov Oncol. 2025;16(1):411.","journal-title":"Discov Oncol"},{"issue":"1","key":"1937_CR16","doi-asserted-by":"publisher","first-page":"e70009","DOI":"10.1002\/hon.70009","volume":"43","author":"D Albano","year":"2025","unstructured":"Albano D, Bianchetti N, Talin A, Dondi F, Re A, Tucci A, Bertagna F. Prognostic role of pretreatment tumor burden and dissemination features from 2-[(18)F]FDG PET\/CT in advanced mantle cell lymphoma. Hematol Oncol. 2025;43(1):e70009.","journal-title":"Hematol Oncol"},{"issue":"1","key":"1937_CR17","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1186\/s12885-023-11333-z","volume":"23","author":"F Wang","year":"2023","unstructured":"Wang F, Cui S, Lu L, Shao X, Yan F, Liu Y, He B, Wang J, Cao Y, Yue Y, et al. Dissemination feature based on PET\/CT is a risk factor for diffuse large B cell lymphoma patients outcome. BMC Cancer. 2023;23(1):1165.","journal-title":"BMC Cancer"},{"issue":"1","key":"1937_CR18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12880-023-01138-8","volume":"23","author":"J Dang","year":"2023","unstructured":"Dang J, Peng X, Wu P, Yao Y, Tan X, Ye Z, Jiang X, Jiang X, Liu Y, Chen S, et al. Predictive value of Dmax and %DeltaSUVmax of (18)F-FDG PET\/CT for the prognosis of patients with diffuse large B-cell lymphoma. BMC Med Imaging. 2023;23(1):173.","journal-title":"BMC Med Imaging"},{"issue":"2","key":"1937_CR19","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s13139-022-00765-3","volume":"57","author":"M Sadik","year":"2023","unstructured":"Sadik M, L\u00f3pez-Urdaneta J, Ul\u00e9n J, Enqvist O, Andersson PO, Kumar R, Tr\u00e4g\u00e5rdh E. Artificial intelligence increases the agreement among physicians classifying focal skeleton\/bone marrow uptake in hodgkin\u2019s lymphoma patients staged with [(18)F]FDG PET\/CT-a retrospective study. Nucl Med Mol Imaging. 2023;57(2):110\u20136.","journal-title":"Nucl Med Mol Imaging"},{"issue":"8","key":"1937_CR20","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.2967\/jnumed.119.227249","volume":"60","author":"SF Barrington","year":"2019","unstructured":"Barrington SF, Meignan M. Time to prepare for risk adaptation in lymphoma by standardizing measurement of metabolic tumor burden. J Nucl Med. 2019;60(8):1096\u2013102.","journal-title":"J Nucl Med"},{"issue":"1","key":"1937_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40658-020-00316-9","volume":"7","author":"E Tragardh","year":"2020","unstructured":"Tragardh E, Borrelli P, Kaboteh R, Gillberg T, Ulen J, Enqvist O, Edenbrandt L. RECOMIA-a cloud-based platform for artificial intelligence research in nuclear medicine and radiology. EJNMMI Phys. 2020;7(1):51.","journal-title":"EJNMMI Phys"},{"issue":"3","key":"1937_CR22","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/cpf.12868","volume":"44","author":"M Sadik","year":"2024","unstructured":"Sadik M, Barrington SF, Tragardh E, Saboury B, Nielsen AL, Jakobsen AL, Gongora JLL, Urdaneta JL, Kumar R, Edenbrandt L. Metabolic tumour volume in hodgkin lymphoma-A comparison between manual and AI-based analysis. Clin Physiol Funct Imaging. 2024;44(3):220\u20137.","journal-title":"Clin Physiol Funct Imaging"},{"issue":"4","key":"1937_CR23","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1007\/s11307-020-01474-z","volume":"22","author":"CN Burggraaff","year":"2020","unstructured":"Burggraaff CN, Rahman F, Kassner I, Pieplenbosch S, Barrington SF, Jauw YWS, Zwezerijnen GJC, Muller S, Hoekstra OS, Zijlstra JM, et al. Optimizing workflows for fast and reliable metabolic tumor volume measurements in diffuse large B cell lymphoma. Mol Imaging Biol. 2020;22(4):1102\u201310.","journal-title":"Mol Imaging Biol"},{"key":"1937_CR24","doi-asserted-by":"publisher","first-page":"994520","DOI":"10.3389\/fimmu.2023.994520","volume":"14","author":"JW Choi","year":"2023","unstructured":"Choi JW, Dean EA, Lu H, Thompson Z, Qi J, Krivenko G, Jain MD, Locke FL, Balagurunathan Y. Repeatability of metabolic tumor burden and lesion Glycolysis between clinical readers. Front Immunol. 2023;14:994520.","journal-title":"Front Immunol"},{"issue":"9","key":"1937_CR25","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.2967\/jnumed.124.267789","volume":"65","author":"R Boellaard","year":"2024","unstructured":"Boellaard R, Buvat I, Nioche C, Ceriani L, Cottereau AS, Guerra L, Hicks RJ, Kanoun S, Kobe C, Loft A, et al. International benchmark for total metabolic tumor volume measurement in baseline (18)F-FDG PET\/CT of lymphoma patients: A milestone toward clinical implementation. J Nucl Med. 2024;65(9):1343\u20138.","journal-title":"J Nucl Med"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-025-01937-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-025-01937-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-025-01937-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:28:07Z","timestamp":1781609287000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12880-025-01937-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1937"],"URL":"https:\/\/doi.org\/10.1186\/s12880-025-01937-1","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Regional Ethics Committee in Gothenburg (#2019\u2009\u2212\u200901274), and the need for written informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ML and OE are employed by and stockholders of Eigenvision AB, which is a company working with research and development in automated image analysis, computer vision, and machine learning. LE is employed by and stockholder of Slicevault AB, which is a company working with streamlining image management for biotech and pharmaceutical companies. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"368"}}